Patents by Inventor Jagadish C. Sircar

Jagadish C. Sircar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
    Publication number: 20040116466
    Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to phenyl-aza-benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small molecules which suppress cytokines and leukocytes.
    Type: Application
    Filed: September 12, 2003
    Publication date: June 17, 2004
    Inventors: Jagadish C. Sircar, Richard J. Thomas, Mark L. Richards, Anjana Sinha
  • Benzimidazole compounds for regulating IgE
    Publication number: 20030100582
    Abstract: This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Application
    Filed: March 20, 2002
    Publication date: May 29, 2003
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Benzimidazole derivatives as modulators of IgE
    Publication number: 20030004203
    Abstract: This invention relates to a family of benzimidazole analogs, which are inhibitors of the IgF response to allergens. These compounds are useful in the treatment of allergy, asthma, or any diseases where IgE is pathogenic.
    Type: Application
    Filed: October 16, 2001
    Publication date: January 2, 2003
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
    Publication number: 20020132808
    Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. This invention also relates to benzimidazole molecules that are cellular proliferation inhibitors and thus are useful as anticancer agents.
    Type: Application
    Filed: February 27, 2002
    Publication date: September 19, 2002
    Inventors: Jagadish C. Sircar, Mark L. Richards
  • Coumarinic compounds having IgE affecting properties
    Patent number: 6451829
    Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: September 17, 2002
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Benzimidazole analogs as down-regulators of IgE
    Patent number: 6369091
    Abstract: This invention relates to a family of diacyl benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: April 9, 2002
    Assignee: Avanir Pharmaceuticals
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Compounds having IgE affecting properties
    Publication number: 20020010343
    Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Application
    Filed: June 14, 2001
    Publication date: January 24, 2002
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Benzimidazole derivatives as modulators of IgE
    Patent number: 6303645
    Abstract: This invention relates to a family of diacyl benzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 16, 2001
    Assignee: Avanir Pharmaceuticals
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • Suppression of the IgE-dependent allergic response by benzimidazole analogs
    Patent number: 6271390
    Abstract: The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.
    Type: Grant
    Filed: May 21, 1999
    Date of Patent: August 7, 2001
    Assignee: Avanir Pharmaceuticals
    Inventors: Jagadish C. Sircar, Mark L. Richards, Michael G. Campbell, Michael W. Major
  • 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
    Patent number: 5494927
    Abstract: The novel 3,5-ditertiarybutyl-4-hydroxy-phenylmethylene derivative of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents having inhibiting activity for 5-lipoxygenase, cyclooxygenase, or both.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: February 27, 1996
    Assignee: Warner-Lambert Company
    Inventors: Wiaczeslaw A. Cetenko, David T. Connor, Jagadish C. Sircar, Roderick J. Sorenson, Paul C. Unangst
  • 3,5-di-t-butyl-4-hydroxyphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
    Patent number: 5393923
    Abstract: The present invention is a novel compound which is a 3,5-di-t-butyl-4-hydroxyphenylmethylhydroxylamine or derivative thereof and a pharmaceutically acceptable acid addition or base salt thereof, pharmaceutical composition and methods of use therefor. The invention compounds are now found to have activity as inhibitors of one or both of cyclooxygenase and 5-lipoxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: February 28, 1995
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David T. Connor, Jagadish C. Sircar
  • Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
    Patent number: 5389661
    Abstract: This invention relates to novel substituted imidazole and triazole derivatives which antagonize the binding of angiotensin II to its receptors. The compounds are useful in the treatment of hypertension, heart failure, glaucoma, and hyperaldosteronism. Methods of making the compounds, novel intermediates useful in the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of using them are also covered.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: February 14, 1995
    Assignee: Warner-Lambert Company
    Inventors: Ila Sircar, Jagadish C. Sircar
  • Imidazole with angiotensin II antagonist properties
    Patent number: 5322950
    Abstract: This invention relates to novel substituted imidazole and triazole derivatives which antagonize the binding of angiotensin II to its receptors. The compounds are useful in the treatment of hypertension, heart failure, glaucoma, and hyperaldosteronism. Methods of making the compounds, novel intermediates useful in the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of using them are also covered.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: June 21, 1994
    Assignee: Warner-Lambert Company
    Inventors: Ila Sircar, Jagadish C. Sircar
  • 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
    Patent number: 5290800
    Abstract: The novel 3,5-ditertiarybutyl-4-hydroxy-phenylmethylene derivative of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents having inhibiting activity for 5-lipoxygenase, cyclooxygenase, or both.
    Type: Grant
    Filed: June 10, 1992
    Date of Patent: March 1, 1994
    Assignee: Warner-Lambert Company
    Inventors: Wiaczeslaw A. Cetenko, David T. Connor, Jagadish C. Sircar, Roderick J. Sorenson, Paul C. Unangst
  • 3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
    Patent number: 5288896
    Abstract: The present invention is a novel compound which is a 3,5-di-t-butyl-4-hydroxyphenylmethylhydroxylamine or derivative thereof and a pharmaceutically acceptable acid addition or base salt thereof, pharmaceutical composition and methods of use therefor. The invention compounds are now found to have activity as inhibitors of one or both of cyclooxygenase and 5-lipoxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever, and the like.
    Type: Grant
    Filed: January 15, 1992
    Date of Patent: February 22, 1994
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David T. Connor, Jagadish C. Sircar
  • 9-Substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors of PNP
    Patent number: 5281708
    Abstract: The present invention is novel 9-substituted-8-hydroxy or -8-halo-9-deazaguanines of the Formula (I) ##STR1## and pharmaceutical compositions and methods of use therefor. The derivatives are inhibitors of purine nucleoside phosphorylase selectively cytotoxic to T-cells but not to B-cells in the presence of 2'-deoxyguanosine and, therefore, are for use in the treatment of autoimmune diseases, gout, psoriasis or rejection of transplantation.The present invention also includes certain novel intermediates of the Formula (II) ##STR2## wherein Z is N.sub.2.sup.+ PF.sub.6.sup.-, or N.sub.2.sup.+ Cl.
    Type: Grant
    Filed: March 4, 1993
    Date of Patent: January 25, 1994
    Assignee: Warner-Lambert Company
    Inventors: Usha Josyula, Jagadish C. Sircar
  • 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
    Patent number: 5236926
    Abstract: The present invention is novel 9-substituted-8-hydroxy or -8-halo-9 deazaguanines and pharmaceutical compositions and methods of use therefor. The derivatives are inhibitors of purine nucleoside phosphorylase selectively cytotoxic to T-cells but not to B-cells in the presence of 2'-deoxyguanosine and, therefore, are for use in the treatment of autoimmune diseases, gout, psoriasis or rejection of transplantation.
    Type: Grant
    Filed: February 3, 1992
    Date of Patent: August 17, 1993
    Assignee: Warner-Lambert Company
    Inventors: Usha Josyula, Jagadish C. Sircar
  • 3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents
    Patent number: 5234939
    Abstract: The novel 3,5-di-tertiary-butyl 4-hydroxyphenylimidazolyl methanones and methanone oximes of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: August 10, 1993
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David T. Connor, Jagadish C. Sircar
  • 3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related compounds as antiinflammatory agents
    Patent number: 5234937
    Abstract: The novel 3,5-di-tertiary-butyl-4-hydroxyphenyloxazolyl methanones and methanone oximes of the present invention are antiinflammatory agents having activity as inhibitors of 5-lipoxygenase, cyclooxygenase or both.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: August 10, 1993
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David T. Connor, Jagadish C. Sircar
  • 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
    Patent number: 5143928
    Abstract: The novel 3,5-ditertiarybutyl-4-hydroxy-phenylmethylene derivative of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents having inhibiting activity for 5-lipoxygenase, cyclooxygenase, or both.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: September 1, 1992
    Assignee: Warner-Lambert Company
    Inventors: Wiaczeslaw A. Cetenko, David T. Connor, Jagadish C. Sircar, Roderick J. Sorenson, Paul C. Unangst